Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Shareholder Meeting (August 2015)
16 slides from Immutep's shareholder meeting presentation, Aug 5, 2015
Slide 1: CEO Presentation Extraordinary General Meeting
ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034 CEO Presentation Extraordinary General Meeting Marc Voigt, Chief Executive Officer July 31, 2015 Sydney, Australia Exhibit 99.1
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN (ASX:PRR; NASDAQ:PBMD; Deutsche Börse:YP1B.DE). These slides have been prepared as a presentation aid only and the information they contain may require further explanati
Slide 3: Prima BioMed
Prima BioMed • Clinical development of immuno-oncology products • Diversified portfolio with LAG-3 programs: Front positioning in growing immuno-oncology revolution of cancer treatment Mission: Emerging leader in immuno-oncology
Slide 4: Prima's development since last AGM
Prima‘s development since last AGM • Acquisition of well - positioned biotech company Immutep closed in Dec 2014 • Strengthening of management team • GSK milestone payment • Completion of CAN-003 trial with promising OS data • Consolidating clinical development of CVac and focus on promising LAG-3 t
Slide 5: Development of the stock since last AGM
Development of the stock since last AGM
Slide 6: i © PRIMA BIOMED
i © PRIMA BIOMED
Slide 7: IMP321 clinical development
IMP321 clinical development • Chemoimmunotherapy Phase IIb trial in metastatic breast cancer Approx. patients IMP321 with paclitaxel vs. paclitaxel and placebo Plan to start Q4 2015 • Phase I in immuno-oncology combination Planning phase of exciting combination study Scientific advice from EMA recei
Slide 8: IMP321: AIPAC Study Design
IMP321: AIPAC Study Design • Multicenter, randomized, double blind, Phase IIb study • Up to 200 patients with metastatic breast cancer • Treatment: first line paclitaxel + IMP321 / placebo • Primary objective: efficacy (as Progression-Free Survival) • Initiation after open-label, safety run-in phase
Slide 9: IMP321: Potential Immuno-oncology combination
IMP321: Potential Immuno-oncology combination Study Design • Multicenter, open label, dose escalation, Phase I study • Planning up to 30 patients with unresectable or metastatic cancer indication with dose escalation • Treatment: Checkpoint inhibitor + IMP321 • Primary objective: safety, tolerabilit
Slide 10: IMP731 for autoimmune diseases
IMP731 for autoimmune diseases • Dec. 2010. GlaxoSmithKline licensed from Immutep, rights to develop LAG-3 depleting antibodies for autoimmune disease - 64m total deal package (~A$118m) + royalties • GSK2831781 is currently in first time in human clinical trials (see NCT02195349 at clinicaltrials.go
Slide 11: IMP701 is partnered with Novartis
IMP701 is partnered with Novartis • IMP701 is an anti-LAG-3 antibody which blocks LAG-3-mediated immune down-regulation • 2012: US biotech CoStim licensed LAG-3 antagonists for cancer from Immutep • Feb. 2014: Novartis bought CoStim for undisclosed sum • Phase I expected to start soon
Slide 12: CVac update
CVac update • CAN-003 – Clear target patient population: in 2nd remission (CR2) of ovarian cancer – Overall Survival Data with positive trend in CR2: >16 months benefit :42Mo CVac vs 25.53Mo OSC – Progression free survival data: >8 months benefit: 12.91Mo for CVac versus PFS=4.94Mo for OSC – Favorab
Slide 13: Outlook FY2016
OUTLOOK FY2016
Slide 14: Funding & cost savings
Funding & cost savings Cash position at 30 th June 2015: $6.76 m SPP with $10 m Ridgeback Capital Investments LP funding: $13.8 m investment* Consolidation of CVac clinical trial program Staff reduction in FY 2015 (over 30%) Delisting from Deutsche Börse -> Trading OTC in Germany at no cost for Prim
Slide 15: Outlook upcoming FY 2016
Outlook upcoming FY 2016 • Start of AIPAC Phase IIb study with IMP321 • Start of immuno-oncology combination Phase I study • Continued development of Phase I study with IMP731 (GSK) • Start of phase I study with IMP701 (Novartis) • Potential new intellectual property • Ongoing research • Ongoing bus
Slide 16: ® PRIMA BIOMED
® PRIMA BIOMED